PCRX Pacira BioSciences
Pacira BioSciences earnings company data as of 7:50 PM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | 0.47 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by PCRX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $11K sold by 1 insider outside a trading plan
- $2.7M sold by 4 insiders under 10b5-1 plans
-
Lauren Riker Senior Vice President, FinancePlanned sale$218K 6,000 shares at $36.32 8.8% of stakeTraded Oct 8 Filed Oct 9
-
Jonathan Slonin Chief Medical OfficerPlanned sale$71K 3,040 shares at $23.23 1.4% of stakeTraded Aug 17 Filed Aug 18
-
Lauren Riker Senior Vice President, FinancePlanned sale$144K 6,115 shares at $23.50 8.9% of stakeTraded Jun 11 Filed Jun 12
-
Kristen Williams Chief Administrative OfficerPlanned sale$228K 10,259 shares at $22.27 5.8% of stakeTraded Jun 4 Filed Jun 5
-
Shawn Cross CFOPlanned sale$326K 12,941 shares at $25.16 11% of stakeTraded Apr 23 Filed Apr 24
-
Shawn Cross CFOPlanned sale$303K 12,059 shares at $25.09 10% of stakeTraded Apr 20–22 Filed Apr 22
-
Jonathan Slonin Chief Medical OfficerPlanned sale$74K 3,261 shares at $22.82 1.4% of stakeTraded Mar 17 Filed Mar 19
-
Mark Froimson DirectorSale$11K 500 shares at $21.81 2.4% of stakeTraded Mar 17 Filed Mar 19
-
Lauren Riker Senior Vice President, FinancePlanned sale$83K 4,000 shares at $20.81 7.1% of stakeTraded Feb 2 Filed Feb 3
-
Kristen Williams Chief Administrative OfficerPlanned sale$270K 13,137 shares at $20.53 9.1% of stakeTraded Feb 2 Filed Feb 3
-
Lauren Riker Senior Vice President, FinancePlanned sale$34K 1,416 shares at $24.24 2.3% of stakeTraded Jan 5 Filed Jan 6
-
Shawn Cross CFOPlanned sale$627K 25,000 shares at $25.07 31% of stakeTraded Dec 9–10 Filed Dec 11, 2025
-
Jonathan Slonin Chief Medical OfficerPlanned sale$95K 3,960 shares at $24.09 2.2% of stakeTraded Nov 17, 2025 Filed Nov 19, 2025
-
Shawn Cross CFOPlanned sale$266K 12,060 shares at $22.09 18% of stakeTraded Nov 10, 2025 Filed Nov 13, 2025
Also filed in the last 12 months, not counted as buying or selling: 14 stock grants, 12 share withholdings for taxes, and 7 option exercises.
SEC filings
Recent issuer filings from EDGAR, 24 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | 10-Q - PCRX - 06.30.2026 | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,8.01,9.01 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | 10-K - PCRX - 03.31.2026 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.